TACTIVE-U: An Interventional Safety and Efficacy Phase 1b/2, Open-Label Umbrella Study To Investigate Tolerability, PK, and Antitumor Activity of Vepdegestrant (ARV-471/PF-07850327), An Oral Proteolysis Targeting Chimera, In Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With ER+ Advanced or Metastatic Breast Cancer, Sub-Study A (ARV-471 In Combination With Abemaciclib)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
Objectives: To assess safety and tolerability of ARV-471 in combination with abemaciclib in participants with ER+/HER2- A/MBC to select a RP2D. To evaluate the overall safety profile. To evaluate antitumor activity of ARV-471 in combination with abemaciclib. To evaluate the plasma exposure of ARV-471, ARV-473, and abemaciclib when ARV-471 and abemaciclib are given in combination.
ARV-471 (); Abemaciclib (); LY2835219 (Abemaciclib)
- Histological or cytological diagnosis of ER+ and HER2- advanced/metastatic breast cancer that is not amendable to surgical resection with curative intent (>1% ER+ stained cells on the most recent tumor biopsy)
- Prior anticancer therapies: up to 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (independent of the setting eg, adjuvant or advanced/metastatic)
- At least 1 measurable lesion as defined by RECIST v1.1
- ECOG PS <1>1>
- Visceral crisis at risk of life-threatening complications in the short term
- Known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
- Newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 14 days prior to enrollment in the study.
- History of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
- Inflammatory breast cancer
- Impaired cardiovascular function or clinically significant cardiovascular diseases
- Concurrent administration of medications, food, or herb supplements that are strong inhibitors and strong/moderate inducers of CYP3A and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
- Renal impairment, not adequate liver function and/or bone marrow function
- Known active infection
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.